Dominican Republic High-Cost Medicines Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF DOMINICAN REPUBLIC HIGH-COST MEDICINES MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.1.1 POLITICAL FACTORS

4.1.2 ECONOMIC FACTORS

4.1.3 SOCIAL FACTORS

4.1.4 TECHNOLOGICAL FACTORS

4.1.5 ENVIRONMENTAL FACTORS

4.1.6 LEGAL FACTORS

4.2 PORTER’S FIVE FORCES ANALYSIS

4.2.1 THREAT OF NEW ENTRANTS

4.2.2 ARGAINING POWER OF SUPPLIERS

4.2.3 BARGAINING POWER OF BUYERS

4.2.4 THREAT OF SUBSTITUTE PRODUCTS

4.2.5 INDUSTRY RIVALRY

4.3 INDUSTRY INSIGHTS– DOMINICAN REPUBLIC HIGH-COST MEDICINES MARKET

4.3.1 PATENT ANALYSIS

4.3.1.1 PATENT LANDSCAPE

4.3.1.2 USPTO NUMBER

4.3.1.3 PATENT EXPIRY

4.3.1.4 EPIO NUMBER

4.3.1.5 PATENT STRENGTH AND QUALITY

4.3.1.6 PATENT CLAIMS

4.3.1.7 PATENT CITATIONS

4.3.1.8 FILE OF PATENT

4.3.1.9 PATENT RECEIVED COUNTRIES

4.3.1.10 TECHNOLOGY BACKGROUND

4.3.2 DRUG TREATMENT RATE BY MATURED MARKETS

4.3.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES

4.3.4 PATIENT FLOW DIAGRAM

4.3.5 KEY PRICING STRATEGIES

4.3.6 KEY PATIENT ENROLLMENT STRATEGIES

4.4 MARKET ACCESS: DOMINICAN REPUBLIC HIGH-COST MEDICINES MARKET

4.4.1 REGULATORY ENTRY PATHWAYS

4.4.2 PUBLIC HEALTH INSURANCE AND REIMBURSEMENT MECHANISMS

4.4.3 PRICING AND PROCUREMENT POLICIES

4.4.4 DISTRIBUTION AND SUPPLY CHAIN FRAMEWORK

4.4.5 HEALTH TECHNOLOGY ASSESSMENT AND INCLUSION CRITERIA

4.4.6 PRIVATE INSURANCE AND OUT-OF-POCKET MARKET

4.4.7 CONCLUSION

5 PIPELINE ANALYSIS — DOMINICAN REPUBLIC HIGH-COST MEDICINES MARKET

5.1 PHASE DISTRIBUTION

5.2 KEY TRENDS IN THE EXPANDED PIPELINE

5.3 GEOGRAPHICAL AND INSTITUTIONAL TRENDS

5.4 STRATEGIC INSIGHTS

6 REGULATION FRAMEWORK: DOMINICAN REPUBLIC HIGH-COST MEDICINES MARKET

6.1 PRODUCT CODES

6.2 CERTIFIED STANDARDS

6.3 SAFETY STANDARDS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING CLINICAL DEMAND FROM COMPLEX AND UNDERSERVED PATIENT POPULATIONS

7.1.2 IMPROVED DIAGNOSTIC CAPABILITIES AND SPECIALIST ACCESS

7.1.3 INCREASED ENTRY OF GLOBAL PHARMA AND BIOSIMILAR PLAYERS

7.2 RESTRAINTS

7.2.1 HIGH COST OF MEDICINES LIMITING ACCESSIBILITY FOR A LARGE SEGMENT OF THE POPULATION

7.2.2 DEPENDENCE ON IMPORTS AFFECTING SUPPLY STABILITY

7.3 OPPORTUNITIES

7.3.1 DEFINED PUBLIC BUDGET FOR HIGH-COST DRUGS

7.3.2 GOVERNMENT POLICY ATTENTION

7.4 CHALLENGES

7.4.1 PRICE SENSITIVITY AND NEGOTIATION PRESSURE

7.4.2 REGULATORY COMPLEXITY AND APPROVAL TIMELINES

8 DOMINICAN REPUBLIC HIGH COST MEDICINES MARKET, BY TYPE

8.1 OVERVIEW

8.2 BIOLOGICS

8.3 INJECTABLES & INFUSIONS

8.4 IMMUNOSUPPRESSANTS

8.5 SPECIALTY PHARMACEUTICALS

8.6 OTHERS

9 DOMINICAN REPUBLIC HIGH COST MEDICINES MARKET, BY THERAPY TYPE

9.1 OVERVIEW

9.2 MULTI-ORGAN SUPPORT SYSTEMS

9.3 RESPIRATORY SUPPORT

9.4 CARDIO VASCULAR SUPPORT

9.5 RENAL SUPPORT

9.6 HEPATIC(LIVER) SUPPORT

10 DOMINICAN REPUBLIC HIGH COST MEDICINES MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.2.1 PUBLIC

10.2.2 PRIVATE

10.2.3 SPECIALIZED TREATMENT CENTERS

10.3 OTHERS

11 DOMINICAN REPUBLIC HIGH-COST MEDICINES MARKET

11.1 COMPANY SHARE ANALYSIS: DOMINICAN REPUBLIC

12 SWOT ANALYSIS

13 COMPANY PROFILES

13.1 PFIZER INC

13.1.1 COMPANY SNAPSHOT

13.1.2 REVENUE ANALYSIS

13.1.3 PRODUCT PORTFOLIO

13.1.4 RECENT DEVELOPMENT

13.2 NOVARTIS AG

13.2.1 COMPANY SNAPSHOT

13.2.2 REVENUE ANALYSIS

13.2.3 PRODUCT PORTFOLIO

13.2.4 RECENT DEVELOPMENTS

13.3 F. HOFFMANN-LA ROCHE LTD

13.3.1 COMPANY SNAPSHOT

13.3.2 REVENUE ANALYSIS

13.3.3 PRODUCT PORTFOLIO

13.3.4 RECENT DEVELOPMENTS

13.4 GRIFOLS, S.A.

13.4.1 COMPANY SNAPSHOT

13.4.2 REVENUE ANALYSIS

13.4.3 PRODUCT PORTFOLIO

13.4.4 RECENT DEVELOPMENT

13.5 SANOFI

13.5.1 COMPANY SNAPSHOT

13.5.2 REVENUE ANALYSIS

13.5.3 PRODUCT PORTFOLIO

13.5.4 RECENT DEVELOPMENT

13.6 ABBVIE INC.

13.6.1 COMPANY SNAPSHOT

13.6.2 REVENUE ANALYSIS

13.6.3 PRODUCT PORTFOLIO

13.6.4 RECENT DEVELOPMENTS

13.7 ALEXION PHARMACEUTICALS, INC

13.7.1 COMPANY SNAPSHOT

13.7.2 PRODUCT PORTFOLIO

13.7.3 RECENT DEVELOPMENT

13.8 AMGEN INC.

13.8.1 COMPANY SNAPSHOT

13.8.2 REVENUE ANALYSIS

13.8.3 PRODUCT PORTFOLIO

13.8.4 RECENT DEVELOPMENT

13.9 ASTELLAS PHARMA INC.

13.9.1 COMPANY SNAPSHOT

13.9.2 REVENUE ANALYSIS

13.9.3 PRODUCT PORTFOLIO

13.9.4 RECENT DEVELOPMENTS

13.1 B. BRAUN SE

13.10.1 COMPANY SNAPSHOT

13.10.2 REVENUE ANALYSIS

13.10.3 PRODUCT PORTFOLIO

13.10.4 RECENT DEVELOPMENT

13.11 BAXTER

13.11.1 COMPANY SNAPSHOT

13.11.2 REVENUE ANALYSIS

13.11.3 PRODUCT PORTFOLIO

13.11.4 RECENT DEVELOPMENT

13.12 BRISTOL-MYERS SQUIBB COMPANY

13.12.1 COMPANY SNAPSHOT

13.12.2 REVENUE ANALYSIS

13.12.3 PRODUCT PORTFOLIO

13.12.4 RECENT DEVELOPMENTS

13.13 GSK PLC.

13.13.1 COMPANY SNAPSHOT

13.13.2 REVENUE ANALYSIS

13.13.3 PRODUCT PORTFOLIO

13.13.4 RECENT DEVELOPMENT

13.14 TAKEDA PHARMACEUTICAL COMPANY LIMITED

13.14.1 COMPANY SNAPSHOT

13.14.2 REVENUE ANALYSIS

13.14.3 PRODUCT PORTFOLIO

13.14.4 RECENT DEVELOPMENT

13.15 TEVA PHARMACEUTICAL INDUSTRIES LTD.

13.15.1 COMPANY SNAPSHOT

13.15.2 REVENUE ANALYSIS

13.15.3 PRODUCT PORTFOLIO

13.15.4 RECENT DEVELOPMENT

14 QUESTIONNAIRE

15 RELATED REPORTS